Conventional wisdom suggests that a high level of the protein prostate specific antigen (PSA) in men with prostate cancer means a poor prognosis. However, this may not always be the case in men with a particular subtype of prostate cancer, according to a new study from Weill Cornell Medicine and NewYork-Presbyterian researchers.

Robert Guimento, a veteran healthcare industry leader, has been appointed president of NewYork-Presbyterian Brooklyn Methodist Hospital, effective August 1. Guimento was formerly senior vice president and chief operating officer for NewYork-Presbyterian Lower Manhattan Hospital.

Levels of air pollution defined as “good” by the Environmental Protection Agency (EPA) may still harm the lungs of cigarette smokers, according to a new study conducted by Weill Cornell Medicine and NewYork-Presbyterian investigators.

The 20th annual “HealthCare’s Most Wired” survey, released by the College of Healthcare Information Management Executives (CHIME), has recognized NewYork-Presbyterian as one of the nation’s “Most Wired” hospitals of 2018.

Dr. Massimo Loda, an internationally renowned molecular pathologist, has been appointed chair of the Department of Pathology and Laboratory Medicine at Weill Cornell Medicine and pathologist-in-chief at NewYork-Presbyterian/Weill Cornell Medical Center, effective Feb. 1.

NewYork-Presbyterian Lower Manhattan Hospital launched Room Service this weekend, a new dining program offering carefully curated fresh meals that are made to order upon request. The program empowers patients to take control of what they eat and when they eat, and the new menu items reflect the cultural diversity of the patient population.

Dr. Dan Landau, an assistant professor of medicine and of physiology and biophysics at Weill Cornell Medicine and a core member of the New York Genome Center, has received a New Innovator Award from the National Institutes of Health for his research on how tumor cells evolve and acquire new mutations to evade cancer therapies.

In a phase three clinical trial, a drug called sorafenib stopped progression of desmoid tumors for two years in 80 percent of patients who completed treatment, a significant increase in progression-free survival compared with placebo. (Progression-free survival is the length of time a patient lives without worsening of the disease).